Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer (Q36956724)

17 August 2017

1 reference

title

Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer (English)

1 reference

17 August 2017

Paraic A Kenny

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Therapeutic Targets

17 August 2017

published in

1 reference

17 August 2017

volume

11

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

1287-1298

1 reference

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

ErbB receptors: directing key signaling networks throughout life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Abrogation of DUSP6 by hypermethylation in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Targeting the EGFR pathway for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Sorafenib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Lapatinib: current status and future directions in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Cetuximab in the treatment of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

FDA drug approval summary: panitumumab (Vectibix).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Where next for gefitinib in patients with lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

ADAMs: modulators of cell–cell and cell–matrix interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Targeting TACE-dependent EGFR ligand shedding in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Three-dimensional extracellular matrix culture models of EGFR signalling and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Tumor reversion: Correction of malignant behavior by microenvironmental cues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Three-dimensional culture models of normal and malignant breast epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Prognostic relevance of basal cytokeratin expression in operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Metastatic potential correlates with enzymatic degradation of basement membrane collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment o

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Conversion of potent MMP inhibitors into selective TACE inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Inflammation-induced modulation of cellular galectin-1 and -3 expression in a model of rat peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Therapeutic strategies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Matrix metalloproteinases and the regulation of tissue remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1287

10.1517/14728222.11.10.1287

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference